March 23 (Reuters) - AstraZenca said on Tuesday it would engage with the independent panel of the U.S. trial of its COVID-19 vaccine and would share its primary analysis with the most up-to-date data with them.
Reporting by Pushkala Aripaka in Bengaluru; Editing by Anil D’Silva
我们的标准: 汤森路透“信任原则”